Goodwin Advises Relay Therapeutics in Exclusive Global License Agreement With Elevar Therapeutics for Up to $75 Million Upfront and in Regulatory Milestones and Up to $425 Million in Commercial Milestones
December 04, 2024
December 04, 2024
BOSTON, Massachusetts, Dec. 4 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Relay Therapeutics, Inc. in its exclusive global license agreement with Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., to develop and commercialize lirafugratinib (RLY-4008), a selective small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) an . . .
The Life Sciences team advised Relay Therapeutics, Inc. in its exclusive global license agreement with Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., to develop and commercialize lirafugratinib (RLY-4008), a selective small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) an . . .